Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Lawrence Tamarkin"'
Autor:
Esther M. Freedman, Giulio F. Paciotti, Naris Nilubol, Lawrence Tamarkin, David G. I. Kingston, Steven K. Libutti, Ziqiang Yuan, Kelli Gaskins, Carmen Sanchez, Electron Kebebew, Shugeng Cao, Jielu Zhao
Publikováno v:
JNCI: Journal of the National Cancer Institute. 110:1019-1029
Background The advantages of nanomedicines include preferential delivery of the payload directly to tumor tissues. CYT-21625 is the novel, first-in-class gold nanomedicine designed to target tumor vasculature and cancer cells by specifically deliveri
Publikováno v:
Oncotarget
Although a number of new systemic therapeutic options in patients with advanced solid cancers have emerged due to the improved knowledge of molecular dysregulation in cancers, the durable, long-term, objective responses infrequently occur. This edito
Autor:
Jielu Zhao, Peggy J. Brodie, Shugeng Cao, Lawrence Tamarkin, Marja S. Huhta, Giulio F. Paciotti, David G. I. Kingston, Lonnie D. Myer, Jay Friedman
Publikováno v:
Bioconjugate Chemistry. 27:2646-2657
The synthesis of a series of thiolated paclitaxel analogs is described as part of a novel nanomedicine program aimed at developing formulations of paclitaxel that will bind to gold nanoparticles for tumor targeted drug delivery. Preliminary evaluatio
Autor:
Frank Malinoski, Margaret Whittaker-Caulk, Nanda Subbarao, Raymond M. David, William C. Zamboni, Paul Brown, Ritu Nalubola, W. Mark Eickhoff, Celia N. Cruz, Katherine M. Tyner, Rajendra Uppoor, Donna Cabral-Lilly, Robert K. Prud'homme, Sabine Haubenreisser, Marcus E. Brewster, Christie M. Sayes, Elaine Morefield, Hripsime Shahbazian, Abigail Jacobs, Nakissa Sadrieh, Jeremy A. Bartlett, Lawrence Tamarkin
Publikováno v:
The AAPS Journal. 17:44-64
At the Product Quality Research Institute (PQRI) Workshop held last January 14-15, 2014, participants from academia, industry, and governmental agencies involved in the development and regulation of nanomedicines discussed the current state of charac
Publikováno v:
Therapeutic delivery. 8(6)
Autor:
Yechezkel Barenholz, Raj Bawa, Sally S. Tinkle, Neil P. Desai, Scott E. McNeil, Gerrit Borchard, Stefan Mühlebach, Lawrence Tamarkin
Publikováno v:
Annals of the New York Academy of Sciences. 1313:35-56
Nanomedicine is the application of nanotechnology to the discipline of medicine: the use of nanoscale materials for the diagnosis, monitoring, control, prevention, and treatment of disease. Nanomedicine holds tremendous promise to revolutionize medic
Publikováno v:
Journal of Clinical Oncology. 37:e14646-e14646
e14646 Background: The clinically-tested CYT-6091 nanomedicine is comprised of TNF alpha (TNF) bound to 27 nm pegylated gold nanoparticles. Preclinical research has shown that CYT-6091 disrupts solid tumor blood vessels, reduces interstitial fluid pr
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Autor:
H. Richard Alexander, William E. Gannon, Nargiza Yuldasheva, Melissa Walker, Lawrence Tamarkin, Giulio F. Paciotti, Geoffrey D. Seidel, Adriana A. Byrnes, Steven K. Libutti
Publikováno v:
Clinical Cancer Research. 16:6139-6149
Purpose: A novel nanomedicine, CYT-6091, constructed by simultaneously binding recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol to the surface of 27-nm colloidal gold particles, was tested in a phase I dose esc
Autor:
Derrick Cox, Jeffrey M. Farma, H. Richard Alexander, Markus Puhlmann, Giulio F. Paciotti, Perry A. Soriano, Lawrence Tamarkin
Publikováno v:
International Journal of Cancer. 120:2474-2480
Tumor necrosis factor (TNF) causes regression of advanced cancers when used in isolation perfusion with melphalan; evidence suggests these effects are mediated via selective yet uncharacterized actions on tumor neovasculature. A novel derivative, col
Publikováno v:
Drug Development Research. 67:47-54
Nanotechnology applied to biological problems represents an emerging field with the potential to offer extremely sensitive diagnostics and targeted cancer therapies. However, to achieve these goals, nanoparticle delivery systems must outwit the many